Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7517.084 | 0.9349 | 0.9066 | 1.4076 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7517.084 | 0.9460 | 0.9226 | 1.4076 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7517.084 | 0.8868 | 0.8364 | 1.4076 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7517.084 | 0.8950 | 0.8484 | 1.4076 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7517.084 | 0.9413 | 0.9158 | 1.4076 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7518.084 | 1.1484 | 1.2203 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7518.084 | 1.1529 | 1.2269 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7518.084 | 1.1715 | 1.2539 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7518.084 | 1.0596 | 1.0894 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7518.084 | 0.9120 | 0.8656 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7518.084 | 1.0067 | 1.0102 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7518.084 | 0.6171 | 0.3892 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7518.084 | 0.8187 | 0.7197 | 1.3244 | |
| MDA-MB-453 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7518.084 | 0.7266 | 0.5714 | 1.3244 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7523.084 | 0.9585 | 0.9086 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7523.084 | 0.9147 | 0.8128 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7523.084 | 0.9547 | 0.9002 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7523.084 | 0.9427 | 0.8740 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7523.084 | 0.8886 | 0.7558 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7523.084 | 0.8555 | 0.6839 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7523.084 | 0.6195 | 0.1796 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7523.084 | 0.5039 | -0.0607 | 0.9069 | |
| MX1 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7523.084 | 0.4103 | -0.2511 | 0.9069 | |
| SK-BR-3 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7526.084 | 0.8723 | 0.8547 | 1.8115 | |
| SK-BR-3 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7526.084 | 0.8890 | 0.8742 | 1.8115 |